Brad Hively bought $9,434 of STLN
director at Oncology Institute, Inc.. 9,056 shares at an average of $1.04, traded Mar 26, 2025, filed Mar 28, 2025.
Score components
- +15RoleDirector
- 0Trade size$9k at market
- 0Relative to holdingsHoldings up 1.4%
- 0Price contextNear the top of the 52-week range
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001079973-25-000521, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 26, 2025 | POpen-market purchase Common Stock | +9,056 | $1.04 | $9,434 | 675,809 | Mar 28, 2025 |
| Mar 26, 2025 | POpen-market purchase Common Warrantderivative | +4,528 | $0.13 | $566 | 4,528 | Mar 28, 2025 |
Related signals
Other insiders at Oncology Institute, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | STLNsell Oncology Institute, Inc. | Brad Hively director | $50k 13,333 shares | -2% | |
| 32Weak | STLNsell Oncology Institute, Inc. | Mark L Pacala director | $200k 50,000 shares | -22% | |
| 50Moderate | STLNsell Oncology Institute, Inc. | M33 Growth I L.P. director, owner | $21M 6,700,000 shares | -48% | |
| 24Weak | STLNsell Oncology Institute, Inc. | Brad Hively director | $82k 20,221 shares | -3% | |
| 48Moderate | Oncology Institute, Inc. | M33 Growth I L.P. director, owner | $2.3M 750,000 shares | -5% | |
| 53Moderate | Oncology Institute, Inc. | Brad Hively director | $5.7M 1,976,137 shares | -77% | |
| 53Moderate | Oncology Institute, Inc. | M33 Growth I L.P. director, owner | $5.4M 2,000,000 shares | -12% | |
| 39Weak | Oncology Institute, Inc. | Brad Hively director | $47k 45,280 shares | +7% | |
| 65Notable | Oncology Institute, Inc. | Richard A Barasch director | $1.4M 1,358,448 shares | +326% | |
| 43Moderate | Oncology Institute, Inc. | Robert Ross Carter Chief Financial Officer | $9,434 9,056 shares | +30% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.